Exclusion Criteria:~* Have previously completed or withdrawn from this study or any other study investigating
solanezumab~* Does not have good venous access, such that intravenous drug delivery or multiple blood draws
would be precluded~* Has allergies to humanized monoclonal antibodies~* Has a known history of human
immunodeficiency virus (HIV), clinically significant multiple or severe drug allergies, or severe posttreatment
hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear IgA dermatosis,
toxic epidermal necrolysis, or exfoliative dermatitis)~* Has a history of chronic alcohol or drug
abuse/dependence~* Is clinically judged by the investigator to be at serious risk for suicide~* Has a recent
(within 6 months before screening) or current laboratory result (if available) indicating a clinically
significant laboratory abnormality~* Has Electrocardiogram (ECG) abnormalities obtained at screening that, in
the opinion of the investigator, are clinically significant with regard to the subject's participation in the
study. Bazett's corrected QT \[QTcB\] interval must be evaluated and must not exceed >458 msec in males or >474
msec in females~* At screening, has alanine transaminase (ALT/SGPT) values greater than or equal to 2 times the
upper limit of normal (ULN) of the performing laboratory, aspartate transaminase (AST/SGOT) values greater than
or equal to 3 times the ULN, or total bilirubin values greater than or equal to 2 times the ULN~* Has had IgG
therapy (sometimes called gamma globulin therapy) within the last year or previous participation in any other
study investigating active immunization against AÎ²~* Requires treatment with other monoclonal antibodies
